Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: zanamivir

« Back to Dashboard
Zanamivir is the generic ingredient in one branded drug marketed by Glaxosmithkline and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

This ingredient has one hundred and sixteen patent family members in forty-six countries.

Three suppliers are listed for this compound.

Summary for Generic Name: zanamivir

Tradenames:1
Patents:2
Applicants:1
NDAs:1
Drug Master File Entries: 0
Suppliers: see list3
Therapeutic Class:Antivirals
Formulation / Manufacturing:see details

Pharmacology for Ingredient: zanamivir

Clinical Trials for: zanamivir

A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza
Status: Recruiting Condition: Influenza, Human

A Study to Evaluate Orally-Administered Oseltamivir and Intravenous Zanamivir in Healthy Subjects
Status: Withdrawn Condition: Healthy Subjects

Pharmacokinetics of Zanamivir After Single and Repeated Dose Infusion Administration in Healthy Chinese Adults
Status: Not yet recruiting Condition: Influenza, Human

A Study of Intravenous Zanamivir in the Treatment of Hospitalized Patients With Influenza Infection
Status: Completed Condition: Influenza, Human

Safety Study to Assess IV Zanamivir for Treatment of Influenza Infection in Patients Who Are in Hospital
Status: Recruiting Condition: Influenza, Human

A Study to Evaluate the Effect of Intravenous Zanamivir on Cardiac Conduction in Healthy Volunteers
Status: Completed Condition: Influenza, Human

Evaluation of Efficacity and Safety of Oseltamivir and Zanamivir
Status: Terminated Condition: Gastric Influenza

Long Term Influenza Prophylaxis With Inhaled Zanamivir or Oral Oseltamivir
Status: Completed Condition: Influenza

Zanamivir Versus Trivalent Split Virus Influenza Vaccine
Status: Completed Condition: Influenza

Special Drug Use Investigation for Relenza® (Zanamivir) (Prophylaxis)
Status: Completed Condition: Influenza, Human

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline
RELENZA
zanamivir
POWDER;INHALATION021036-001Jul 26, 1999RXYes5,648,379<disabled><disabled>
Glaxosmithkline
RELENZA
zanamivir
POWDER;INHALATION021036-001Jul 26, 1999RXYes6,294,572<disabled>YY<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: zanamivir

Country Document Number Publication Date
Egypt20597Sep 30, 1999
China1057260Dec 25, 1991
Yugoslavia74591Jun 24, 1994
China1184108Jun 10, 1998
World Intellectual Property Organization (WIPO)9116320Oct 31, 1991
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc